Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01348269
Other study ID # CZOL446HDE38T
Secondary ID
Status Completed
Phase Phase 3
First received May 2, 2011
Last updated June 7, 2017
Start date May 2011
Est. completion date August 26, 2015

Study information

Verified date April 2017
Source Wuerzburg University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary aim is to test the reduction of bone marrow edema syndrome after a singular intravenous treatment with Zoledronic Acid within 6 weeks compared to placebo. The volume of the edema is defined as biometric data measured by the use of MRT before and six weeks after treatment. The hypothesis has to be checked whether Zoledronic Acid is efficient in the treatment of painful bone marrow edema. A statistically significant reduction of the edema in the MRT is considered as evidence for efficacy.


Recruitment information / eligibility

Status Completed
Enrollment 63
Est. completion date August 26, 2015
Est. primary completion date August 26, 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Men: age over = 18 years or women: age over = 18 years with finished reproductivity according to the following definition:

- = 12 month persistent natural (spontaneous) amenorrhoea (women aged <50: additionally: FSH >40MIE/ml and estrogen deficiency of <30pg/ml or a negative estrogen test)

- status post hysterectomy and / or bilateral oophorectomy

- finished reproduction planning

- secure diagnosis of bone marrow edema using MRT

- current osteologic basic laboratory values (= 4 weeks before V2) according to DVO criteria

- presence of an personally signed informed consent for the participation in the study

Exclusion Criteria:

- - subchondral bone loss or already occurred cartilage damage due to the bone marrow edema

- reactive bone marrow edema with advanced arthrotic changes in the adjacent joint (grade III and IV according to Kellgren and Lawrence)

- patients with edematous changes in bone marrow due to the diagnosis of M. Sudeck / algodystrophy / Complex Regional Pain Syndrome (CRPS)

- patients with known hypo- and hyperparathyroidism, osteogenesis imperfecta, osteomalacia, M. Paget or another systemic skeletal diseases, except osteoporosis

- patients with bone necrosis in the painful skeletal region

- patients with infectious process at the affected bone or the adjacent joint and adjacent soft parts, respectively

- patients with diagnosed or assumed rheumatoid arthritis, Lupus erythematodes, collagenosis or vasculitides

- patients with advanced renal insufficiency (GFR according to Cockcroft

/ Gault = 40 ml/min/KO)

- patients with malignant diseases with osseous manifestation in anamnesis/history

- status post malignant basic/primary disease with large dosed chemotherapy

- current or massive dose therapy completed before less than 6 weeks (>7.5mg prednisolon equivalent) with glucocorticoids

- patients with a malignant tumor disease within the past 5 years, independent from the affected organ system and independent from the implemented treatment, the presence of a relapse or metastatic invasion, except basal cell carcinoma and squamous-cell carcinoma of the skin Current treatment due to uveitis

- vague/ambiguous hyper- or hypocalcemia, hyper- or hypophosphatemia

- etiological vague/ambiguous AP-increase

- symptomatic renal calculus or nephrocalcinosis within 2 years before V2

- recent fracture within the last 3 months independent of the localisation

- non consolidated fractures

- previous treatment with i.v. bisphosphonates within the last 12 months

- previous treatment with oral bisphosphonates within the last 12 months and longer than 3 months

- pre-treatment with prostacyclin analogs (Ilomedin® / Iloprost®) within the past 6 months

- Current treatment due to inflammatory diseases of the jaw area as well as planned tooth extractions or tooth extractions less than 6 months ago or oral surgery implant treatment

- pregnancy or nursing period

- patients immediately involved in the conduction of the trial and relatives

- patients with current proceedings related to the bone marrow edema

- patients for which the participation in the study carries an increased risk under consideration of the health condition due to the assessment of the investigator

- participation in another clinical trial within 30 days before study start or during the trial

- participation of patient who might be dependent on the investigator, also the spouse, parents or children

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Aclasta
1 x intravenous non-current drip (infusion)
Placebo
NaCl Solution

Locations

Country Name City State
Germany Department of trauma, hand, reconstructive and plastic, University of Wuerzburg Wuerzburg Bavaria
Germany Orthopedic Center for Musculoskeletal Research, Orthopedic Department, University of Wuerzburg Wuerzburg Bavaria

Sponsors (3)

Lead Sponsor Collaborator
Wuerzburg University Hospital Crolll Gmbh, University of Wuerzburg

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Reduction of the Edema area Week 6 after study start
Secondary Reduction of pain (VAS) Week 0, 3, 6
Secondary Quality of life (Qualeffo-41 questionnaire - Quality of life questionnaire of the European Foundation for Osteoporosis) Week 0, 3, 6
Secondary Subjective estimation of medical condition (PDI) Week 0, 3, 6
Secondary Number of additional medicinal visits Week 3, 6
Secondary Number of days of illness Week 3, 6
Secondary Number of Participants with Adverse Events as a Measure of Safety and Tolerability including changes in the following parameters according to DVO guidelines: Calcium, Phosphate, Creatinin-Clearance (Cockcroft-Gault), Alkaline Phosphatase, ?GT, CRP Week 3, 6
See also
  Status Clinical Trial Phase
Completed NCT03110224 - SCP® Observational Study of the Knee
Recruiting NCT03699046 - Evaluating the Effectiveness of Subchondroplasty for Treating Bone Marrow Lesions of the Knee N/A
Recruiting NCT05596591 - Focused Extracorporeal Shockwave Therapy for Knee Arthritis N/A
Completed NCT03941977 - Treatment of Bone Marrow Edema Lesions of the Knee With Percutaneous Grafting N/A
Recruiting NCT04895228 - Impact of Sacroiliac Joint Injection on Bone Marrow Edema N/A
Completed NCT03112200 - Subchondroplasty® Knee RCT N/A
Active, not recruiting NCT03494660 - SCP Hip Outcomes Study
Completed NCT01621893 - Evaluation of Subchondroplasty™ for Defects Associated With Bone Marrow Lesions
Terminated NCT03112122 - Study for the Treatment of the Bone Marrow Edema:Core Decompression VS Bone Marrow Concentrate (BMC) VS Bone Substitute Phase 4
Completed NCT03430219 - Subchondroplasty Procedure in Patients With Bone Marrow Lesions
Recruiting NCT03921489 - Subchondroplasty for Treatment of Bone Marrow Edema in the Foot and Ankle
Terminated NCT03829644 - Lumbar Bracing for People With Type I Modic Changes N/A
Recruiting NCT04963127 - Prospective Study of Diagnostic Accuracy of Spectral CT for the Detection of Bone Marrow Edema
Completed NCT04905394 - Clinical and Radiological Outcomes of Subchondroplasty in the Treatment of Bone Marrow Edema of the Knee N/A